DermTech, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bret Christensen
- Full Time Employees
- 206
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 11099 North Torrey Pines Road La Jolla CA United States of America 92037
- IPO Date
- Aug 10, 2017
- CIK
- 0001651944
- Website
- dermtech.com
- Similar Companies
- Business
- DermTech, Inc. is a molecular diagnostic company primarily engaged in developing and marketing novel non-invasive genomic tests for the diagnosis and management of melanoma and other skin cancers in the United States. Its core products include the DermTech Melanoma Test, which provides a non-invasive method to rule out melanoma with a high negative predictive value through genomic analysis of skin samples collected using the DermTech Smart Sticker, an adhesive patch that collects skin tissue non-invasively. The company also offers contract research services and technology platforms to pharmaceutical companies to facilitate clinical trials and development of dermatology drugs, including gene expression assays for conditions such as psoriasis, atopic dermatitis, and skin aging. DermTech operates a CLIA-certified molecular laboratory and markets its products primarily to dermatologists, pathologists, and oncology practitioners. Founded in 2010 and headquartered in San Diego, California, DermTech’s precision dermatology solutions aim to transform skin cancer diagnostics from invasive biopsy procedures to objective, non-invasive genomics-based assessments. In recent major developments, DermTech, Inc. underwent significant corporate changes including filing for Chapter 11 bankruptcy reorganization in June 2024 and proceeding to Chapter 11 liquidation, which was approved in July 2025. Subsequently, its assets, including the DermTech Melanoma Test, were acquired by DermTech, LLC, a newly formed entity that now operates under new ownership and management since August 2024. DermTech, LLC signed a lease for a new headquarters and state-of-the-art molecular laboratory facility in San Diego in 2025, continuing to offer the DermTech Melanoma Test and expanding its precision dermatology product offerings and customer support nationwide. The company remains focused on revolutionary, cost-effective genomic solutions for early melanoma detection and ongoing development of products targeting non-melanoma skin cancers and UV-related precancerous genomic changes.
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Why Is DermTech (DMTK) Stock Down 26% Today?
Crude Oil Rises 1%; DermTech Shares Plummet
DermTech Files for Voluntary Chapter 11 Protection
DermTech Reports First-Quarter 2024 Financial Results
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
DermTech Reports Fourth-Quarter 2023 Financial Results
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
DMTK DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses to Contact the Firm
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DermTech, Inc. (DMTK)